PharmaSGP (PSG.DE)

Executive Summary

PharmaSGP SE is a German pharmaceutical company specializing in branded over-the-counter (OTC) medicines for pain management and dermatology. Listed on the Frankfurt Stock Exchange (PSG.DE), the company operates primarily in Germany, leveraging a portfolio of established brands that generate stable revenues. With a market capitalization of approximately €380 million, PharmaSGP focuses on the entire product lifecycle from development to commercialization. The company's strategy emphasizes self-medication trends and consumer healthcare, positioning it within the growing OTC market. Financially, it has transitioned to a publicly traded entity, offering transparency and potential for shareholder returns. Looking ahead, PharmaSGP aims to expand its brand presence through organic growth and targeted acquisitions, while managing regulatory and competitive risks. The company's reliance on the German market presents both stability and concentration risk, but its established brands and disciplined approach suggest a resilient business model.

Upcoming Catalysts (preview)

• Q4 2026Launch of new OTC dermatology product70% success
• Q2 2027Expansion into neighboring European markets via partnerships50% success
• Q3 2026Announcement of dividend policy or special dividend60% success